The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 10, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions

Schizophrenia Disorders

Interventions

DRUG

Brexpiprazole long-acting injection

A single injection was administered.

Trial Locations (1)

RECRUITING

Beijing Anding Hospital Capital Medical University, Beijing

All Listed Sponsors

lead

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

INDUSTRY